Biomarin Pharmaceutical Inc (BMRN)
Debt-to-assets ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | 595,138 | 594,627 | 594,116 | 593,605 | 593,095 | 592,586 | 1,084,990 | 1,084,010 | 1,083,020 | 1,082,030 | 1,081,050 | 1,080,060 | 1,079,080 | 1,078,090 | 1,077,110 | 1,076,130 | 1,075,140 | 1,074,160 | 1,073,200 | 486,713 |
Total assets | US$ in thousands | 6,988,940 | 6,851,200 | 7,067,120 | 6,872,670 | 6,841,600 | 6,758,160 | 6,563,170 | 6,433,700 | 6,375,070 | 6,264,040 | 6,145,840 | 6,062,710 | 6,004,770 | 5,977,480 | 5,898,500 | 5,805,050 | 5,848,020 | 6,158,090 | 5,302,110 | 4,722,840 |
Debt-to-assets ratio | 0.09 | 0.09 | 0.08 | 0.09 | 0.09 | 0.09 | 0.17 | 0.17 | 0.17 | 0.17 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.19 | 0.18 | 0.17 | 0.20 | 0.10 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $595,138K ÷ $6,988,940K
= 0.09
The debt-to-assets ratio for Biomarin Pharmaceutical Inc has shown a relatively stable trend over the period from March 31, 2020, to December 31, 2024, with values ranging between 0.08 and 0.20. This ratio indicates the proportion of the company's total debt relative to its total assets. A lower debt-to-assets ratio suggests a lower level of financial risk, as it implies that the company relies less on debt financing and has a stronger financial position.
In the given period, Biomarin's debt-to-assets ratio fluctuated within a relatively narrow range, with a slight increase observed in mid-2020, followed by a gradual decline and stabilization around 0.17 to 0.18. However, a notable decrease was observed in the ratio for the last quarter of 2023 and the first two quarters of 2024, dropping to 0.08 and 0.09, respectively. This significant dip might indicate a reduction in the company's debt burden or an increase in asset value during these periods.
Overall, Biomarin Pharmaceutical Inc's consistent maintenance of a moderate debt-to-assets ratio implies a balanced capital structure and sound financial management. It suggests that the company has been effectively managing its debt levels in proportion to its asset base, which can enhance investor confidence and long-term sustainability.
Peer comparison
Dec 31, 2024